abstract background: This study was conducted to determine whether there is an association between urinary neutrophil gelatinaseassociated lipocalin (uNGAL) and urinary transforming growth factorβ1 (uTGFβ1) with lupus nephritis (LN) disease activity. Methods: Urine samples from 18 LN patients were collected every month for six months then examined for uNGAL, uTGFβ1, and renal domain Systemic Lupus Erythematosus Disease Activity Index (SLEDAI) score. results: The uNGAL levels were significantly different between active and inactive LN (P , 0.05). uTGFβ1 levels were not different between active and inactive LN (P . 0.05). There was a significant correlation between uNGAL levels and renal domain SLEDAI score (r = 0.417, P , 0.05). There was no correlation between uTGFβ1 levels and renal domain SLEDAI score (r = 0.031, P . 0.05). conclusIon: uNGAL is better than uTGFβ1 for differentiation of active and inactive LN. uNGAL can be considered as a biomarker to monitor LN disease activity. 
Introduction
Systemic lupus erythematosus (SLE) is a connective tissue disease with very diverse clinical pictures. This disease involves many organs of the body, and its course is characte rized by remissions and exacerbations. Although its etiology is unknown, SLE occurrence has been linked to several predis posing factors such as genetic abnormalities, viral infections, and hormonal disorders. SLE is characterized by autoimmune lesions and formation of multiple antibodies against various organ tissues such as joints, lungs, muscles, and kidneys. [1] [2] [3] The prevalence of renal involvement in SLE, called lupus nephritis (LN), is varied between 31% and 65% (average of 40%) at the beginning of SLE. Manifestations of renal insuf ficiency are often found in SLE before other clinical symptoms appear. Asians and Africans experience LN more frequently than other races. LN tends to be a chronic disease, with flares that require repeated treatments over the years. Generally, it is the most serious manifestation of SLE, with nephritis and infection as the frequent cause of death in the first ten years of disease. 1, 2 Since SLE patients with nephritis are often asymp tomatic, the urinalysis should be performed on all patients suspected of having SLE. Current laboratory markers for LN such as proteinuria, urine protein creatinine ratio, creatinine clearance, antidsDNA, and complement levels are still unsat isfactory. Proteinuria still has some limitations, its sensitivity and specificity cannot differentiate between kidney activity and damage in LN. Persistent proteinuria does not always indicate an ongoing inflammatory process in the kidneys, which may be contributed by preexisting chronic lesion or by a new damage in the kidney during the disease course. Flare of nephritis can occur without an observable increase in the degree of proteinuria. 2, 3 LN disease course is characterized by remissions and acti vation of the disease, and its activity can be determined using renal domain Systemic Lupus Erythematosus Disease Activity Index (SLEDAI) score. The renal domain SLEDAI score is determined from urinalysis result. LN is defined as active when the score is .0 and defined inactive if the score is 0. A kidney biopsy is the gold standard for LN diagnosis. It also provides information of LN histological classification, relative activity, and chronicity level in the glomerulus. However, it is an invasive procedure and serial biopsy is also impractical for LN monitoring. Currently, there is a necessity for a new Several studies have been conducted to find biomarkers that can assess LN disease activity. For example is the urinary biomarker, which samples are easy to collect and thought to be more accurate in distinguishing kidney disease from other organs. 5, 6 Neutrophil gelatinaseassociated lipocalin (NGAL) is a protein with a molecular weight of 25 kDa and a member of the lipocalin family. It is mainly synthesized by epithelial cells of proximal tubules, the loop of Henle, and collecting ducts of the kidney. NGAL has an important role in cell regeneration and growth after renal injury. It is found in most parts of the kidney so there is possibility that this protein can be used as a marker of kidney damage. [7] [8] [9] [10] Transforming growth factorβ1 (TGFβ1) is an immunoregulatory (antiinflammatory) cytokine that blocks IL2 production (leading to inhibition of Tcell proliferation). It also regulates CD4 Tcell differentiation, decreases the production of IL6, IL1, and TNFα by mac rophages, and stimulates Thelper type 3 (Th3) development. Th3 exert their action primarily through TGF family cytokines, particularly beta1. TGFß1 serves as a modulator and a sup pressor of Th1 cytokines; therefore, Th3 cytokines play an important role in balancing Th1 and Th2 cytokines to pre vent the severe cellmediated inflammatory reaction. TGFβ1 also largely involved in renal fibrosis through its proangiogenic and profibrotic effects: induction of collagen gene expres sion, increased transcription of extracellular matrix recep tor, and inhibition of proteins that involve in extracellular matrix breakdown. [11] [12] [13] [14] [15] Many studies have been done concerning urinary NGAL (uNGAL) roles on glomerulonephritis disorders, but there are a few studies investigating its role in LN. The results from uNGAL study in pediatric patients showed that uNGAL increased about three months prior to LN activation (flares).
16
TGFβ1 study with experimental animals showed that TGFβ1 could be used to predict the occurrence of LN acti vation (flare) and to identify advanced and irreversible kidney disease phase. 17 TGFβ1 mRNA study on urine sediment of LN patients showed a significant increase of TGFβ1 mRNA in the active disease condition, and it was decreased in parallel with reduced disease activity. However, there are also other studies reporting no correlation between urinary TGFβ1 (uTGFβ1) and LN activity status. 18 Therefore, this study was conducted to determine uNGAL and uTGFβ1 levels in active and inactive LN patients and to find the correlation between uNGAL and uTGFβ1 levels with renal domain SLEDAI score of LN patients. Samples were collected between December 2011 and 2013. This study was approved by the Ethics Committee of Medical Faculty of Brawijaya University and Dr. Saiful Anwar Hospital. Informed consent was obtained from all participants, and the research was conducted in accordance with principles of the Declaration of Helsinki. Inclusion cri teria were female aged 15-50 years, who did not suffer from congenital kidney disorder, diabetes, uncontrolled hyperten sion, and infection, since women are more affected by lupus compared to men with a ratio of 5:1. Exclusion criteria were patients with renal trauma and other diseases that can affect kidney function.
Methods
ln disease activity. LN disease activity was deter mined based on renal domain SLEDAI score. Each score was obtained from urinalysis results. Renal domain SLEDAI score consists of:
• urinary cast: finding of granular or erythrocyte castscore 4; no granular or erythrocyte cast -score 0; • hematuria: erythrocyte .5/hpf -score 4; erythro cyte ,5/hpf without infection, kidney stones, or othersscore 0; • Proteinuria: proteinuria .0.5 g/24 hours or .3+ -score 4; proteinuria ,0.5 g/24 hours or #3+ -score 0; • leukosituria/pyuria: leukocyte .5/hpf -score 4; leu kocyte ,5/hpf without urinary tract infection -score 0.
The total score for renal domain SLEDAI score is 0-16 (0, 4, 8, 12, 16) . 19 LN was defined as active when the renal domain SLE DAI score was .0, while LN was defined as inactive if the renal domain SLEDAI score was 0. LN activity was assessed if renal domain SLEDAI score increased to .0 compared to the previous score. Renal domain SLEDAI score was deter mined monthly for six months.
urine samples. Every urine sample was collected in a sterile container using the aseptic method, centrifuged imme diately, and stored at −80 °C until analyzed. Each sample was examined for complete urinalysis, uNGAL, uTGFβ1, and renal domain SLEDAI score.
ungal and utgF-β1 measurement. We used RayBio  human Lipocalin2/NGAL enzymelinked immu nosorbent assay (ELISA) kit (ELHLipocalin2001) to measure uNGAL level. It is an in vitro ELISA for the quan titative measurement of human Lipocalin2 in urine. This assay employs an antibody specific for human Lipocalin2 coated on a 96well plate. RnD Systems Quantikine  ELISA human TGFβ kit (DB100B) was used to measure uTGFβ1 level. This assay employs the quantitative sand wich enzyme immunoassay (ELISA) technique. A mono clonal antibody specific for TGFβ1 has been precoated onto a microplate.
statistical analysis. Statistical analysis was performed using SPSS version 20.0 for Windows software. The corre lation between uNGAL and uTGFβ1 levels and LN dis ease activity was analyzed with Pearson test. Differences of uNGAL and uTGFβ1 levels on LN disease activity (divided into active and inactive diseases) and control subjects were analyzed with oneway ANOVA. A Pvalue of ,0.05 was considered as statistically significant. results sample characteristics. The samples in this study were LN patients and healthy subjects. Eighteen healthy subjects (female gender; mean age 28.78 years) served as a control group. All LN patients were also female with age ranging from 17 to 40 years (mean age 26.5 years) ( Table 1) . We per formed a twoyear followup on 30 patients with LN, but only 18 patients could be followed up regularly for six months. We could not complete the followup on the other 12 patients until six months because four patients died during the followup and eight patients went to another hospital.
During the study period, we managed to follow up 18 LN patients regularly each month. Every patient was followed for six months. Finally, we had 108 samples from 18 patients. From 108 samples, we divided LN disease activity into active and inactive LN based on the total score of renal domain SLEDAI score. Seventyseven (71.3%) samples were active LN and 31 (28.7%) were inactive LN.
The difference in ungal levels between active and inactive nl patients. The monthly differences in uNGAL levels between active and inactive LN patients are shown in Table 2 . Combined data of uNGAL levels between active and inactive LN patients from month 1 to month 6 gave a Pvalue of 0.001 (P , 0.05), showing that uNGAL levels between active and inactive LN were significantly different. The uNGAL lev els for active LN were higher (mean = 11,258.04 pg/mL) than inactive LN (mean = 3,826.5 pg/mL) (Fig. 1) . The uNGAL levels in control group (mean = 346.00 pg/mL) were signifi cantly lower than LN patients (P , 0.05).
The difference in utgF-β1 levels between active and inactive nl patients. The monthly differences in uTGFβ1 levels between active and inactive LN patients are shown in Table 2 . Combined data of uTGFβ1 levels between active and inactive LN patients from month 1 to month 6 gave a Pvalue of 0.518 (P . 0.05), showing that uTGFβ1 lev els between active LN (mean = 93.32 pg/mL) and inactive LN (mean = 112.11 pg/mL) were not significantly different (Fig. 2) . The uTGFβ1 levels in control group (mean = 23.73 pg/mL) were lower than LN patients, but not significantly different (P . 0.05). correlation of ungal levels with renal domain sledaI score of ln patients. The monthly correlation between uNGAL levels and renal domain SLEDAI score of LN patients were statistically analyzed using Pearson correla tion test (Table 3) .
The Pearson correlation test on combined data (from month 1 to month 6) of uNGAL levels and renal domain SLEDAI score showed a correlation value (r) of 0.417 with P , 0.05. This result showed a significant correlation between uNGAL levels and renal domain SLEDAI score. In other words, increased uNGAL levels are correlated with increased renal domain SLEDAI score and vice versa.
correlation of utgF-β1 levels with renal domain sledaI score of ln patients. The monthly correlation between uTGFβ1 levels and renal domain SLEDAI score of LN patients was statistically analyzed using Pearson correla tion test (Table 3) .
The Pearson correlation test on combined data (from month 1 to month 6) of uTGFβ1 levels and renal domain SLEDAI score showed a correlation value (r) of 0.031 with P = 0.747 (P . 0.05). This result showed no significant correla tion between uTGFβ1 levels and renal domain SLEDAI score. In other words, increased uTGFβ1 levels were not correlated with increased renal domain SLEDAI score and vice versa.
For more information about uNGAL levels, uTGFβ1 levels and renal domain SLEDAI score from Month 1 to Month 6, please refers to Supplementary Table 1, 2, and 3.
discussion
The difference in ungal levels between active and inactive ln patients. In this study, uNGAL levels were significantly different between active and inactive LN patients. This result is crucial to evaluate LN disease activity. If uNGAL levels are increased than the previous results, we can assume that LN is active and it will need a proper inter vention. uNGAL is known as a biomarker for acute kidney injury (AKI) with high sensitivity and specificity. [20] [21] [22] Renal epithelial cells will express and excrete very large number of NGAL in urine within 30 minutes in the event of damage caused by ischemiareperfusion injury, nephrotoxins, sep sis and chronicprogressive changes. 23 An earlier study by Pitashny et al on 70 adult patients with SLE (32 of them with the active renal disease) showed that uNGAL levels were sig nificantly higher in LN than nonrenal SLE patients or healthy controls. 24 Brunner et al also found that among patients with SLE, higher uNGAL levels could distinguish patients with or without active kidney disease.
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The difference in utgF-β1 levels between active and inactive ln patients. Our results showed no significant difference in uTGFβ1 levels between active and inactive LN patients. It showed that uTGFβ1 levels are more likely to describe the chronic condition of kidney damage in LN patients, characterized by fibrosis of kidney tissue. Increased TGFβ1 in target organ can cause dysregulation of tissue repair, progressive fibrogenesis, and endorgan damage. 14, 17 The previous study by Saxena et al measured the TGFβ1 expression in lupusprone mice, both in lymphoid tissues (spleen) and target organ (kidney). They found no correla tion between uTGFβ1 levels and glomerular activity index, but there was a strong correlation between uTGFβ1 levels, chronicity index, and tubulointerstitial index, which describes local fibrosis. Their data also showed that tissue and urinary TGFβ1 levels correlated with the degree of organ damage in the kidneys, especially with chronic fibrotic lesions but not with inflammatory lesions. The role of TGFβ1 in fibrosis process also has been reported by Yamamoto and Loskutoff. They found increased expression of TGFβ mRNA and PAI1 mRNA over time in kidney tissue of lupusprone mice after three hours of intraperitoneal injection with TGFβ. TGFβ and PAI1 may contribute to the kidney pathology by stimulating extracellular matrix accumulation and trigger sclerotic and fibrotic changes. 26 Our findings are different from the previous study by Hammad et al. In their study, latent and active TGFβ1 levels were assessed in the plasma and urine of all patients (32 children with active SLE and 15 healthy children as control group) before starting immunosuppressive therapy. They found that patients with symptomatic nephritis had significantly elevated urinary active TGFβ1 levels in comparison to those with silent nephritis. 26 These contradictory results were correlated with those of Tamaki et al, who found that only latent TGFβ1 lev els increased in chronic renal fibrosis. Its levels were elevated in parallel with the degree of renal fibrosis, while active TGFβ1 levels were low, suggesting that in acute nephritis, TGFβ1 may be activated shortly after being secreted, while in the chronic phase, most TGFβ1 may exist for a long time in tissues as the latent type and may then be activated little by little. [27] [28] [29] TGFβ1 is secreted from many cellular sources as a latent form and activated mainly by proteases to exert its biological function. 30 It is known that the production of both active and latent TGFβ1 was impaired in lymphocytes isolated from SLE patients. 31 A later study showed that in more than half of the patients with SLE, the isolated Tcell population had no TGFβ1 mRNA expression and at least one member of the TGFβ1 pathway was also missing. 32 In addition, normal TGFβ1 activation was lower in SLE patients with severe organ damage than those with a Systemic Lupus International Collaborating Clinics (SLICC) score of 0. 30 The correlation between lower TGFβ1 levels and decreased CD4+, CD8+, and NK cell frequency suggests that the reduction of these cell subsets might be responsible for the decreased levels of TGFβ1. 33 The counterregulatory mechanisms between latent and active TGFβ1 remain largely unknown; it will need fur ther investigation to demonstrate the functional complexity of latent vs. active TGFβ1 in renal fibrosis and inflammation.
correlation of ungal levels with renal domain sledaI score of ln patients. Overall, this study showed that uNGAL levels were positively correlated with renal domain SLEDAI score in LN patients, suggesting that uNGAL may be useful as a marker for monitoring LN disease activity. Our study showed significant correlations between uNGAL and renal domain SLEDAI score of LN patient only on months 2 and 4. One may assume that the SLEDAI score was not sensitive enough to every renal flare in patients who already manifest baseline indica tors of nephritis. For instance, patients who have a renal flare manifested by an increase in urinary protein excretion from already significant baseline levels of proteinuria will not be picked up by SLEDAI, which has already awarded the maximal score possible for proteinuria. 10 The other rea son is that NGAL measurements may be influenced by a number of coexisting variables, including chronic kidney disease, chronic hypertension, systemic infections, inflam matory conditions, anemia, hypoxia, and malignancies. In this context, NGAL might be a useful biomarker for kidney disease, but comorbid conditions when evaluating NGAL values should be considered because it can affect serum and urine NGAL levels. 34, 35 A longitudinal study was performed by Suzuki et al in 85 pediatric SLE patients. They found that uNGAL (rather than plasma NGAL) was correlated to worsening of global or renal disease activity as assessed by SLEDAI in SLE patients, and urinary NGAL may be an important biomarker for assess ing renal disease activity in SLE patients. 16 Another longi tudinal study was performed by Hinze et al in 111 pediatric SLE patients. They assessed SLE disease activity by using three standard indices of disease activity. Plasma and urinary NGAL levels were measured every three months. Their study found a significant increase in urinary NGAL/creatinine lev els that were detected three months prior to LN worsening that was assessed on three disease activity indices.
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correlation of utgF-β1 levels with renal domain sledaI score of ln patients. In this study, we found no correlation between uTGFβ1 levels with renal domain SLEDAI score of LN patients. A study by Hammad et al also found that increased uTGFβ1 levels did not represent systemic disease activity because its levels were not cor related with SLEDAI. Increased uTGFβ1 levels are not a simple epiphenomenon of increased excretion of proteinu ria; uTGFβ1 levels in patients with symptomatic nephritis did not correlate with proteinuria degree. 27 Jin et al found no significant correlation between total TGFβ1 in serum with SLEDAI score. This was probably because of huge variability and diversity in the type of involve ment by SLE. It is known that the use of immunosuppressive therapies, for example, glucocorticosteroids, upregulates TGFβ1 production by immune cells and expands regulatory Tcells. Thus, more aggressive immunosuppressive therapy in patients with high disease activity may increase total TGFβ1 levels to almost the same levels in patients with low or moderate disease activity. However, it remains unclear why active TGFβ1, which might be biologically more meaningful than total TGFβ1, has no association with SLICC and degree of renal damage. 30 Effects of corticosteroid on uTGFβ1 levels were also investigated by Goumenos et al and Haramaki et al. They found that uTGFβ1 levels were significantly lower in patients who showed a significant improvement in renal function with immunosuppressive therapy when compared with patients with no signs of improvement. Levels of uTGFβ1 correlated positively with cellular crescents in kidney biopsy. According to their results, very high uTGFβ1 levels are followed by poor response to immunosuppressive therapy and probably repre sent development of irreversible damage in kidney tissue of patients with crescentic nephritis. [37] [38] [39] study limitation. This study had several limitations. First, the number of enrolled patients was relatively small. Sec ond, samples for assessment of LN disease activity were highly varied every month because of treatment and other factors that
